Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INO 5401

Next Previous
Drug Profile

INO 5401

Alternative Names: INO-5401

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; Regeneron Pharmaceuticals
  • Class Antineoplastics; DNA; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Cancer
  • Discontinued Urogenital cancer

Most Recent Events

  • 30 May 2025 Adverse events data from a phase Ib trial in Cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 09 May 2025 Inovio Pharmaceuticals completes phase II clinical trials in Urogenital cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in USA and Spain (IM) (NCT03502785)
  • 09 Jan 2025 Inovio Pharmaceuticals plans to conduct a controlled phase II trial in Glioblastoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top